BiotechTube
Firefly Bio

Firefly Bio

San Francisco, United States· Est.
fireflybiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $94M

Overview

Firefly Bio is a private, pre-clinical-stage biotech founded in 2020, focusing on the convergence of targeted protein degradation and antibody-drug conjugate technology. The company's core innovation is its Degronimid platform, designed to generate Degrader Antibody Conjugates (DACs) that selectively deliver protein-degrading payloads to tumor cells. Backed by a $94 million Series A financing and a leadership team with deep ADC and oncology expertise from companies like Genentech, Merck, and Lilly, Firefly aims to address limitations of traditional ADCs by accessing novel, potent payload mechanisms. The company is currently in the platform and discovery phase, building its pipeline for oncology indications.

Oncology

Technology Platform

Degronimid platform for developing Degrader Antibody Conjugates (DACs), which combine antibody targeting with protein degrader payloads.

Funding History

2
Total raised:$94M
Venture$94M
SeedUndisclosed

Opportunities

Firefly Bio operates at the convergence of two high-growth therapeutic fields: antibody-drug conjugates and targeted protein degradation.
Success with its DAC platform could unlock novel cancer treatments with improved specificity and efficacy over current ADCs, addressing a multi-billion dollar market.
The strong investor backing and experienced team provide a solid foundation to pursue this ambitious goal.

Risk Factors

The company faces significant technical risks in successfully conjugating complex protein degrader molecules to antibodies while maintaining drug-like properties.
As a pre-clinical platform company, it must validate its novel approach in vivo, which is unproven.
Intense competition in both the ADC and protein degradation spaces also presents a market and differentiation risk.

Competitive Landscape

Firefly competes in the crowded and innovative ADC space, where companies are developing next-generation payloads beyond traditional cytotoxics. It also competes with biotechs developing tissue-targeted degraders and systemic PROTACs. Key differentiators will be the efficacy and specificity of its Degronimid platform compared to other novel conjugate technologies and degradation strategies.

More companies in Biologics / Biosimilars →More companies in United States →